ANI Pharmaceuticals (ANIP) has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding on worldwide net revenues of Iluvien and Yutiq for a one-time payment of $17.25M. Under the terms of the agreement, upon making the buyout payment, no further royalty is due to SWK on net revenues beginning January 1, 2025, forward. ANI funded the buyout with cash on hand.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- Positive Outlook for ANI Pharmaceuticals: FDA Approval and Strategic Moves Drive Buy Rating
- ANI Pharmaceuticals announces FDA approval for expansion of Iluvien label
- ANI Pharmaceuticals initiated with a Buy at Jefferies
- ANI Pharmaceuticals initiated with an Overweight at JPMorgan
- ANI Pharmaceuticals Discusses Alimera Acquisition Challenges